Email updates

Keep up to date with the latest news and content from Clinical and Translational Allergy and BioMed Central.

This article is part of the supplement: Food Allergy and Anaphylaxis Meeting (FAAM 2013): Abstracts

Open Access Open Badges Poster presentation

A new OIT protocol for severe peanut allergy

AK Kukkonen*, A Pelkonen, M Mäkelä, H Voutilainen, S Mäkinen-Kiljunen and Helsinki University Central Hospital

  • * Corresponding author: AK Kukkonen

Author Affiliations

Skin and Allergy Hospital, Pediatric Department, Helsinki University Central Hospital, Helsinki, Finland

For all author emails, please log on.

Clinical and Translational Allergy 2013, 3(Suppl 3):P6  doi:10.1186/2045-7022-3-S3-P6

The electronic version of this article is the complete one and can be found online at:

Published:25 July 2013

© 2013 Kukkonen et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Oral immunotherapy (OIT) may reduce the risk for severe allergic reaction at accidental ingestion of peanut. We aimed at developing a peanut OIT protocol with home-based dose escalations for 6-18 year-old children with moderate to severe allergic reaction in a double-blind placebo-controlled challenge (DBPCFC).


Our pirmary outcome was the increase in the amount of ingested peanut protein tolerated in DBPCFC by peanut OIT. Secondarily we investigated safety of OIT. Since September 2011, peanut-sensitized patients with moderate to severe allergic reaction (1) in DBPCFC were included. Bronchial hyperreactivity, exhaled nitric oxide, and food allergy related quality of life (2, 3) were evaluated pre and post OIT. Roasted and defatted peanut flour, allergenity of which was assessed using microarray inhibition, was mixed with margarine (no milk or soy) in 3 concentrations at hospital kitchen. A teaspoonful of peanut-margarine mixture weight 1.7 g. From week 20 and on, we used real peanuts. The first dose of 0.1 mg peanut protein was taken at hospital and the same dose continued daily at home. Dose escalations occurred at home every 1 to 2 weeks. The patient returned to the hospital 7 times for dose escalation. Antihistamine was taken daily until 2 weeks from reaching the maintenance dose of 4 peanuts. As safety procedures, exercise was forbidden one hour post each dose and the day of escalation, and the patients carried adrenalin auto-injectors.


In November 2012, 18 patients mean age 9 (6-16) y have entered the OIT. At DBPCFC, the median dose of peanut protein causing moderate to severe allergic reaction was 55 mg (1/4 peanut), range 5 to 255 mg, 10/18 had received 1 to 3 doses of adrenalin as treatment for anaphylactic reaction at challenge. The median (range) serum peanut specific-IgE was 89 (1.8-817) kU/L and peanut skin prick test was 10 (6-16). Fourteen children had asthma. Two patients discontinued the study; one was non-compliant and one had continuous nausea. One patient has received adrenalin after dose escalation at home; 2 patients have taken antihistamines once due to urticaria. Mild oro-pharyngeal itching requiring no medication was common.


Based on our preliminary results it seems possible to develop a peanut OIT protocol with home-based dose escalations also in anaphylactic patients.

Disclosure of interest

None declared.


  1. Hourihane , et al.:

    Clin Exp Allergy. 2005, 35:1227-33. PubMed Abstract | Publisher Full Text OpenURL

  2. Dunn Galvin A, et al.:

    Clin Exp Allergy. 2008, 38:977-86. PubMed Abstract | Publisher Full Text OpenURL

  3. Flokstra-de Blok, et al.:

    J Allergy Clin Immunol. 2008, 122:139-44. PubMed Abstract | Publisher Full Text OpenURL